Clinical trials: Complication in Systemic Lupus Erythematosus
Lupus Nephritis
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
This is a prospective single-arm multi-center trial to evaluate the efficacy and safety of O-triple regimen in initial active LN patients
- Trial name
- NCT07767188
- Testing
- obinutuzumab (RO5072759)
- Where
- 14 sites in China
- Volunteers
- 70 people
- Sponsor
- Zhao Minghui
Lupus Nephritis
BAFF Levels and Lupus Nephritis (LN)
B-cell activating factor (BAFF), serves as a vital survival and differentiation factor for normal B-cell development. BAFF levels have been associated with the clinical activity of SLE in humans.
- Trial name
- BAFF (NCT04369495)
- Testing
- BAFF serum levels
- Sponsor
- Universidad de Antioquia
Systemic Lupus Erythematosus, Lupus Nephritis
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
This is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK（pharmacokinetic）/PD（pharmacodynamics ） of UB-VV410 in adult subjects with clinically active treatment-refractory SLE.
- Trial name
- NCT07109986
- Testing
- UB-VV410
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
This study evaluates the safety and efficacy of YTS109 cells in adults with refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus-Immune Thrombocytopenia (SLE-ITP).
- Trial name
- NCT06943937
- Testing
- YTS109 cell injection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Lupus Nephritis
Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
All patients with SLE that will be admitted in internal medicine department from August 2019 to January 2021 are eligible to be targeted and included in the study.
- Trial name
- NCT03958851
- Testing
- Doppler ultrasonography of renal arteries, Renal biopsy, kidney function tests
- Volunteers
- 120 people
- Sponsor
- Assiut University
Lupus Nephritis (LN), Chronic Kidney Disease
Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis
Lupus nephritis is one of the most serious complications of lupus, an autoimmune disease in which the immune system mistakenly attacks the body's own tissues.
- Conditions
- Lupus Nephritis (LN), Chronic Kidney Disease, SGLT 2 Inhibitors, Systemic Lupus Erythematosus
- Trial name
- DAPA-LN (NCT07678203)
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Civil Juan I. Menchaca
Lupus Nephritis (LN)
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
- Trial name
- NCT07363460
- Testing
- HSK39297 200mgQD, HSK39297 300mgQD
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02256150
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Lupus Nephritis
Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
- Trial name
- NCT00876616
- Testing
- Tacrolimus+Mycophenolate mofetil, Cyclophosphamide
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhi-Hong Liu, M.D.
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III
Safety and Efficacy of ONT01 in Lupus
ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA.
- Conditions
- Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III
- Trial name
- NCT07107659
- Testing
- ONT01 is a small molecule CD11b modulator.
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Hospital for Special Surgery, New York
Lupus Nephritis
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the…
- Trial name
- NCT02770170
- Testing
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Lupus Nephritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants.
- Trial name
- NCT01085097
- Testing
- Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 46 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Lupus Nephritis
Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis.
- Trial name
- NCT01042457
- Testing
- Mycophenolate mofetil
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- Chulalongkorn University
Lupus Nephritis
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest.
- Trial name
- OBSErve-LN (NCT06527872)
- Testing
- None (Observational study)
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Lupus Nephritis
Daratumumab to Treat Active Lupus Nephritis
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
- Trial name
- NCT04868838
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Lupus Nephritis
A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
This 2 arm study will compare the efficacy and safety of CellCept plus corticosteroids, versus cyclophosphamide plus corticosteroids in the induction phase followed by azathioprine in the maintenance phase, in maintaining…
- Trial name
- NCT00425438
- Testing
- Mycophenolate Mofetil, Corticosteroids, Azathioprine
- Where
- 11 sites in China
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease.
- Trial name
- REBIOLUP (NCT04449991)
- Testing
- Repeat kidney biopsy
- Where
- Sweden
- Volunteers
- 206 people
- Sponsor
- Karolinska Institutet
Lupus Nephritis
Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis
This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.
- Trial name
- NCT04522505
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Corestemchemon, Inc.
Systemic Lupus Erythematosus
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD). Secondary objectives: Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active…
- Trial name
- NCT06518668
- Testing
- NKX019, Cyclophosphamide LD
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hospital for Special Surgery, New York
Lupus Nephritis
Clinical Trial Treatment in Lupus Nephritis
The treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of lupus nephritis in the early '80s. In recent years, alternative regimens have appeared in both the induction and maintenance with…
- Trial name
- Csa-LES (NCT01299922)
- Testing
- cyclosporine +mycophenolic acid+prednison, Mycophenolic Acid + prednison
- Where
- Spain
- Sponsor
- Hospital Universitario Fundación Alcorcón